Aa
Antiviral effects of HBIG & vaccine on HBs antigen seroclearance for chronic HBV
Format: Abstract
Send to
J Gastroenterol. 2016 Nov;51(11):1073-1080. Epub 2016 Mar 4.
Antiviral effects of anti-HBs immunoglobulin and vaccine on HBs antigen seroclearance for chronic hepatitis B infection.
Tsuge M1,2,3, Hiraga N1,3, Uchida T1,3, Kan H1,3, Miyaki E1,3, Masaki K1,3, Ono A1,3, Nakahara T1,3, Abe-Chayama H1,3, Zhang Y1,3, Naswa MG1,3, Kawaoka T1,3, Miki D1,3,4, Imamura M1,3, Kawakami Y1,3, Aikata H1,3, Ochi H1,3, Hayes CN1,3, Chayama K5,6,7.
Author information
Abstract
BACKGROUND AND AIMS:
Interferon and nucleotide/nucleoside analogues are the main treatments for chronic hepatitis B. These drugs effectively reduce serum hepatitis B virus (HBV) DNA titers but fail to sufficiently reduce hepatitis B surface antigen (HBsAg) levels. Following the recent identification of sodium taurocholate cotransporting polypeptide as a receptor for HBV entry, inhibition of HBV entry has become an attractive therapeutic target for chronic hepatitis B treatment. We therefore evaluated the antiviral effects of antibody to HBsAg (anti-HBs) immunoglobulin (HBIG), which can inhibit HBV entry, by in an vivo study and a clinical trial.
METHODS:
In the in vivo study, HBV-infected mice were generated from human hepatocyte chimeric mice and treated with HBIG. A clinical trial evaluating HBIG therapy in patients was also performed.
RESULTS:
In the mouse study, HBV DNA titers were reduced and serum HBsAg titers decreased to undetectable levels following high-dose HBIG injection. On the basis of this result, eight chronic hepatitis B patients, who had received long-term nucleotide analogue treatment, were treated with monthly HBIG injections as an additional treatment. After 1 year of treatment, an HBsAg level reduction of more than 1 log IU/mL was observed in four patients, and three patients became anti-HBs positive. No adverse events occurred during HBIG therapy.
CONCLUSION:
These results suggest that monthly HBIG injection might benefit patients with chronic hepatitis B whose HBsAg titer becomes lower following long-term nucleotide/nucleoside analogue treatment.
KEYWORDS:
Anti-HBs immunoglobulin; Chronic hepatitis B; Hepatitis B surface antigen loss; Human hepatocyte chimeric mouse
Send to
J Gastroenterol. 2016 Nov;51(11):1073-1080. Epub 2016 Mar 4.
Antiviral effects of anti-HBs immunoglobulin and vaccine on HBs antigen seroclearance for chronic hepatitis B infection.
Tsuge M1,2,3, Hiraga N1,3, Uchida T1,3, Kan H1,3, Miyaki E1,3, Masaki K1,3, Ono A1,3, Nakahara T1,3, Abe-Chayama H1,3, Zhang Y1,3, Naswa MG1,3, Kawaoka T1,3, Miki D1,3,4, Imamura M1,3, Kawakami Y1,3, Aikata H1,3, Ochi H1,3, Hayes CN1,3, Chayama K5,6,7.
Author information
Abstract
BACKGROUND AND AIMS:
Interferon and nucleotide/nucleoside analogues are the main treatments for chronic hepatitis B. These drugs effectively reduce serum hepatitis B virus (HBV) DNA titers but fail to sufficiently reduce hepatitis B surface antigen (HBsAg) levels. Following the recent identification of sodium taurocholate cotransporting polypeptide as a receptor for HBV entry, inhibition of HBV entry has become an attractive therapeutic target for chronic hepatitis B treatment. We therefore evaluated the antiviral effects of antibody to HBsAg (anti-HBs) immunoglobulin (HBIG), which can inhibit HBV entry, by in an vivo study and a clinical trial.
METHODS:
In the in vivo study, HBV-infected mice were generated from human hepatocyte chimeric mice and treated with HBIG. A clinical trial evaluating HBIG therapy in patients was also performed.
RESULTS:
In the mouse study, HBV DNA titers were reduced and serum HBsAg titers decreased to undetectable levels following high-dose HBIG injection. On the basis of this result, eight chronic hepatitis B patients, who had received long-term nucleotide analogue treatment, were treated with monthly HBIG injections as an additional treatment. After 1 year of treatment, an HBsAg level reduction of more than 1 log IU/mL was observed in four patients, and three patients became anti-HBs positive. No adverse events occurred during HBIG therapy.
CONCLUSION:
These results suggest that monthly HBIG injection might benefit patients with chronic hepatitis B whose HBsAg titer becomes lower following long-term nucleotide/nucleoside analogue treatment.
KEYWORDS:
Anti-HBs immunoglobulin; Chronic hepatitis B; Hepatitis B surface antigen loss; Human hepatocyte chimeric mouse
Have an Answer?
You are reading content posted in the Hepatitis B Community
A list of national and international resources and hotlines to help connect you to needed health and medical services.
Herpes sores blister, then burst, scab and heal.
Herpes spreads by oral, vaginal and anal sex.
STIs are the most common cause of genital sores.
Condoms are the most effective way to prevent HIV and STDs.
PrEP is used by people with high risk to prevent HIV infection.
